Credit Suisse’s Marinus Pharmaceuticals, Inc MRNS Stock Holding History

Credit Suisse’s Portfolio MRNS Stock Details MRNS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-24,000	Closed	-$285K	–	4459
2021 Q4	$285K	Buy	+24,000	New	+$277K	﹤0.01%	4138

Other funds holding MRNS

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return

Adage Capital Partners

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Antara Capital New York $30.2K AUM 5.24% 1-Year Est. Return

Credit Suisse's MRNS Position: Q3 2022 in Review

Credit Suisse sold out of Marinus Pharmaceuticals, Inc (MRNS) in Q3 2022, closing a stake of 20 shares.

Credit Suisse first reported a position in MRNS in Q2 2015 and held it in 9 quarters. The position peaked at $10.3M in Q3 2018. 69 funds tracked by Wall St. Rank hold MRNS as of Q3 2022.

Credit Suisse reported no remaining Marinus Pharmaceuticals, Inc position as of Q3 2022 after selling out during the quarter.
Credit Suisse sold 20 Marinus Pharmaceuticals, Inc shares in Q3 2022.
Credit Suisse first reported a position in Marinus Pharmaceuticals, Inc in Q2 2015 and held it in 9 quarters.
Credit Suisse's Marinus Pharmaceuticals, Inc position peaked at $10.3M in Q3 2018.
69 funds tracked by Wall St. Rank held Marinus Pharmaceuticals, Inc as of Q3 2022.

Based on Credit Suisse's 13F filing for Q3 2022, filed 10 Nov 2022.